Shockwave Announces Updated Time for CAD III Investor Webcast Event in Conjunction with TCT Connect

Rhea-AI Summary

Shockwave Medical (NASDAQ: SWAV) has rescheduled its CAD III Investor Webcast Event to take place on October 15, 2020, at 2:30 p.m. ET, during TCT Connect. The webcast will feature the presentation of the DISRUPT CAD III trial results by a principal investigator, a panel discussion, and a Q&A session. Interested attendees can access the live audio webcast through the Investors section on the company's website. Shockwave is dedicated to advancing the treatment of calcified cardiovascular disease using its innovative Intravascular Lithotripsy technology.

Positive

• Updated webcast timing shows ongoing engagement with investors.
• The DISRUPT CAD III trial results presentation indicates progress in clinical studies.

Negative

• None.

SANTA CLARA, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced updated timing for the company’s CAD III Investor Webcast Event to be held in conjunction with TCT Connect. The event will now take place at 2:30 p.m. eastern time on Thursday, October 15, 2020.

The webcast event will include a presentation of the DISRUPT CAD III trial results by one of the study’s principal investigators as well as a panel discussion and an interactive question and answer session. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at https://ir.shockwavemedical.com. A replay of the webcast will be available following the presentation.

About Shockwave Medical, Inc.

Shockwave is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. Shockwave aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes. To view an animation of the IVL procedure and for more information, visit www.shockwavemedical.com.

Media Contact:
Scott Shadiow
+1.317.432.9210
sshadiow@shockwavemedical.com

Investor Contact:
Debbie Kaster
dkaster@shockwavemedical.com

FAQ

What is the new timing for Shockwave Medical's CAD III Investor Webcast Event?

The CAD III Investor Webcast Event is now scheduled for October 15, 2020, at 2:30 p.m. ET.

What will be discussed during the web event for CAD III?

The webcast will feature the presentation of the DISRUPT CAD III trial results and include a panel discussion and Q&A session.

Where can I access the Shockwave Medical webcast?

The webcast can be accessed from the Investors section of Shockwave Medical's website.

What is Intravascular Lithotripsy (IVL) by Shockwave Medical?

IVL is a minimally invasive technology developed by Shockwave Medical that uses sonic pressure waves to treat calcified plaque in cardiovascular disease.